CD22 CAR T-cell associated hematologic toxicities, endothelial activation and relationship to neurotoxicity

• DOI: 10.1136/jitc-2022-005898
• Publication Date: 2023-06-09T14:02:26Z
• Authors: Jennifer Jess; Bonnie Yates; Alina Dulau-Florea; Kevin Parker; Jon Inglefield; Dan Lichtenstein; Fiorella Schischlik; Martin Ongkeko; Yanyu Wang; Shilpa Shahani; Ann Cullinane; Hannah Smith; Eli Kane; Lauren Little; Dong Chen; Terry J Fry; Haneen Shalabi; Hao-Wei Wang; Ansuman Satpathy; Jay Lozier; Nirali N Shah
• Keywords: Neurotoxicity

Hematologic toxicities, including coagulopathy, endothelial activation, and cytopenias, with CD19-targeted chimeric antigen receptor (CAR) T-cell therapies correlate cytokine release syndrome (CRS) neurotoxicity severity, but little is known about the extended toxicity profiles of CAR T-cells targeting alternative antigens. This report characterizes hematologic toxicities seen following CD22 their relationship to CRS neurotoxicity.